Ferric Carboxymaltose is an iron replacement product and chemically, an iron carbohydrate complex. FDA approved on July 25, 2013.
Ferric carboxymaltose is an iron replacement product indicated for the treatment of iron deficiency anemia in patients ≥1 year of age who have an intolerance to, or unsatisfactory response from, oral iron therapy. It is also indicated in adult patients who have non-dialysis-dependent chronic kidney disease.
Kazan State Medical Universety, Kazan, Tatarstan, Russian Federation
University Hospital Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain
Hospital Universitari de Bellvtige, Hospitalet de Llobregat, Barcelona, Spain
Iwaya Primary Health Centre, Iwaya, Lagos, Nigeria
Sheikh Jidda General Hospital, Kano, Nigeria
Nuhu Bammali Maternity Hospital, Kano, Nigeria
Hippokration General Hospital of Thessaloniki, Third Department of Cardiology (Aristotle University of Thessaloniki), Thessaloníki, Macedonia, Greece
St. Christopher's Hospital for Children, Philadelphia, Pennsylvania, United States
University of Iowa, Iowa City, Iowa, United States
Cohen Children's Medical Center, New Hyde Park, New York, United States
FPG Fondazione Policlinico Gemelli IRCCS, Roma, Italy
Jorvi Hospital, Espoo, HUS, Finland
Christian Medical College, Vellore, Vellore, Tamil Nadu, India
Department of Obstetrics and Gynaecology, University Hospital Basel, Basel, Switzerland
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.